ALLO vs CVS · rev $22.0K vs P/E 16, rev $402.07B
Allogene Therapeutics Inc (ALLO) versus CVS Health Corp (CVS) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
ALLO currently screens at market cap $258.1M. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Not investment advice. Open the ALLO and CVS stock pages for the full models.
Not investment advice.